192 related articles for article (PubMed ID: 17558688)
1. Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
Potolog-Nahari C; Fishman A; Cohen I
Gynecol Endocrinol; 2007 May; 23(5):290-4. PubMed ID: 17558688
[TBL] [Abstract][Full Text] [Related]
2. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
Beck-Fruchter R; Weiss A; Shalev E
Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
[TBL] [Abstract][Full Text] [Related]
3. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
4. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
5. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
7. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
[TBL] [Abstract][Full Text] [Related]
8. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
Blumenfeld Z; von Wolff M
Hum Reprod Update; 2008; 14(6):543-52. PubMed ID: 18824495
[TBL] [Abstract][Full Text] [Related]
9. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
12. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
13. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up.
von Wolff M; Kämmerer U; Kollmann Z; Santi A; Dietl J; Frambach T
Fertil Steril; 2011 Jan; 95(1):452-4. PubMed ID: 20869706
[TBL] [Abstract][Full Text] [Related]
14. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
[TBL] [Abstract][Full Text] [Related]
15. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
16. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
18. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
19. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori F; Demeestere I
Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
[No Abstract] [Full Text] [Related]
20. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]